Catalent Clarifies Novo Nordisk Ownership of Former Bloomington, Indiana Site
October 16, 2025 — Catalent, a leading global contract development and manufacturing organization (CDMO), today issued a statement to address recent inaccuracies in media coverage regarding the ownership of one of its former sites located in Bloomington, Indiana.
As of December 2024, the Bloomington, Indiana site is no longer part of Catalent’s network. The site is now fully owned and operated by Novo Nordisk following the acquisition of Catalent by Novo Holdings in 2024, and the strategic divestiture of the Bloomington site and two other sterile fill-finish sites to Novo Nordisk.
Despite having announced and confirmed the ownership change, some recent reports continue to reference the Bloomington facility as part of Catalent’s network. These references are inaccurate and outdated. While legacy naming conventions such as “Catalent Indiana” or “Catalent Indiana, LLC” may still appear in certain regulatory filings, Catalent has no ownership, operational involvement, or oversight of the site.
Catalent remains a premier CDMO with over 40 facilities worldwide, delivering innovative solutions for pharma, biologics, and consumer health organizations. Catalent’s teams across the globe are committed to driving improved outcomes for customers and patients through an unwavering commitment to service excellence and a patient-first approach.